Published in Stem Cells Dev on February 25, 2013
Survival and biodistribution of xenogenic adipose mesenchymal stem cells is not affected by the degree of inflammation in arthritis. PLoS One (2015) 1.42
Production of mesenchymal stromal/stem cells according to good manufacturing practices: a review. Stem Cell Res Ther (2013) 1.10
Comparative study of immune regulatory properties of stem cells derived from different tissues. Stem Cells Dev (2013) 1.08
Comparing the Immunomodulatory Properties of Bone Marrow, Adipose Tissue, and Birth-Associated Tissue Mesenchymal Stromal Cells. Front Immunol (2015) 1.06
High-resolution molecular validation of self-renewal and spontaneous differentiation in clinical-grade adipose-tissue derived human mesenchymal stem cells. J Cell Biochem (2014) 1.03
Immunoregulatory properties of clinical grade mesenchymal stromal cells: evidence, uncertainties, and clinical application. Stem Cell Res Ther (2013) 1.03
Spheroid Culture of Mesenchymal Stem Cells. Stem Cells Int (2015) 0.96
International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials. Cytotherapy (2015) 0.95
A robust and reproducible animal serum-free culture method for clinical-grade bone marrow-derived mesenchymal stromal cells. Cytotechnology (2015) 0.91
CD146 expression on mesenchymal stem cells is associated with their vascular smooth muscle commitment. J Cell Mol Med (2013) 0.90
Optimization of human mesenchymal stem cell manufacturing: the effects of animal/xeno-free media. Sci Rep (2015) 0.89
The multiple functional roles of mesenchymal stem cells in participating in treating liver diseases. J Cell Mol Med (2014) 0.89
Partnership between platelet-rich plasma and mesenchymal stem cells: in vitro experience. Muscles Ligaments Tendons J (2014) 0.87
Freshly thawed and continuously cultured human bone marrow-derived mesenchymal stromal cells comparably ameliorate allergic airways inflammation in immunocompetent mice. Stem Cells Transl Med (2015) 0.86
Immune regulatory properties of CD117(pos) amniotic fluid stem cells vary according to gestational age. Stem Cells Dev (2015) 0.85
A robust potency assay highlights significant donor variation of human mesenchymal stem/progenitor cell immune modulatory capacity and extended radio-resistance. Stem Cell Res Ther (2015) 0.84
Standard requirement of a microbiological quality control program for the manufacture of human mesenchymal stem cells for clinical use. Stem Cells Dev (2014) 0.84
Differential and transferable modulatory effects of mesenchymal stromal cell-derived extracellular vesicles on T, B and NK cell functions. Sci Rep (2016) 0.83
Towards an advanced therapy medicinal product based on mesenchymal stromal cells isolated from the umbilical cord tissue: quality and safety data. Stem Cell Res Ther (2014) 0.82
Bottlenecks in the Efficient Use of Advanced Therapy Medicinal Products Based on Mesenchymal Stromal Cells. Stem Cells Int (2015) 0.79
Mesenchymal stromal (stem) cells to improve solid organ transplant outcome: lessons from the initial clinical trials. Curr Opin Organ Transplant (2013) 0.79
Effects of a ceramic biomaterial on immune modulatory properties and differentiation potential of human mesenchymal stromal cells of different origin. Tissue Eng Part A (2014) 0.78
Early growth response-2 signaling mediates immunomodulatory effects of human multipotential stromal cells. Stem Cells Dev (2013) 0.78
Umbilical Cord Tissue-Derived Cells as Therapeutic Agents. Stem Cells Int (2015) 0.78
Interaction between Mesenchymal Stem Cells and B-Cells. Int J Mol Sci (2016) 0.78
Stem Cells and Their Mediators - Next Generation Therapy for Bronchopulmonary Dysplasia. Front Med (Lausanne) (2015) 0.77
Nanosized UCMSC-derived extracellular vesicles but not conditioned medium exclusively inhibit the inflammatory response of stimulated T cells: implications for nanomedicine. Theranostics (2017) 0.77
Mesenchymal stromal cells from pooled mononuclear cells of multiple bone marrow donors as rescue therapy in pediatric severe steroid-refractory graft-versus-host disease: a multicenter survey. Haematologica (2016) 0.76
Adipose-derived mesenchymal stem cell administration does not improve corneal graft survival outcome. PLoS One (2015) 0.76
In vitro cytokine licensing induces persistent permissive chromatin at the Indoleamine 2,3-dioxygenase promoter. Cytotherapy (2016) 0.76
Generation of mesenchymal stromal cells from cord blood: evaluation of in vitro quality parameters prior to clinical use. Stem Cell Res Ther (2017) 0.75
Optimizing conditions for labeling of mesenchymal stromal cells (MSCs) with gold nanoparticles: a prerequisite for in vivo tracking of MSCs. J Nanobiotechnology (2017) 0.75
Ultrasound-Mediated Mesenchymal Stem Cells Transfection as a Targeted Cancer Therapy Platform. Sci Rep (2017) 0.75
Mesenchymal stromal cells for treatment of the acute respiratory distress syndrome: The beginning of the story. J Intensive Care Soc (2015) 0.75
The hUC-MSCs cell line CCRC-1 represents a novel, safe and high-yielding HDCs for the production of human viral vaccines. Sci Rep (2017) 0.75
Pathogen reduction through additive-free short-wave UV light irradiation retains the optimal efficacy of human platelet lysate for the expansion of human bone marrow mesenchymal stem cells. PLoS One (2017) 0.75
Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy (2006) 37.55
Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet (2008) 12.59
Mesenchymal stem cells in health and disease. Nat Rev Immunol (2008) 11.14
Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell (2009) 7.62
Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell (2008) 7.47
Human mesenchymal stem cells modulate B-cell functions. Blood (2005) 5.12
Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells (2005) 4.26
Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease. Gut (2011) 3.81
IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur J Immunol (2008) 3.53
Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells (2007) 3.49
Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood (2007) 3.38
Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. Lancet Neurol (2012) 3.15
Mesenchymal stem cell-based tissue regeneration is governed by recipient T lymphocytes via IFN-γ and TNF-α. Nat Med (2011) 3.11
Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial. JAMA (2012) 2.85
Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression. Stem Cells (2009) 2.71
Characterization of the optimal culture conditions for clinical scale production of human mesenchymal stem cells. Stem Cells (2005) 2.53
Same or not the same? Comparison of adipose tissue-derived versus bone marrow-derived mesenchymal stem and stromal cells. Stem Cells Dev (2012) 2.47
Multipotent mesenchymal stromal cells and the innate immune system. Nat Rev Immunol (2012) 2.36
Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur J Immunol (2005) 2.34
Retention of multilineage differentiation potential of mesenchymal cells during proliferation in response to FGF. Biochem Biophys Res Commun (2001) 2.24
Clinical-grade production of human mesenchymal stromal cells: occurrence of aneuploidy without transformation. Blood (2009) 2.20
Human alternatives to fetal bovine serum for the expansion of mesenchymal stromal cells from bone marrow. Stem Cells (2009) 2.19
Good manufacturing practices production of mesenchymal stem/stromal cells. Hum Gene Ther (2010) 2.15
Toll-like receptors 3 and 4 are expressed by human bone marrow-derived mesenchymal stem cells and can inhibit their T-cell modulatory activity by impairing Notch signaling. Stem Cells (2007) 2.12
Analysis of tissues following mesenchymal stromal cell therapy in humans indicates limited long-term engraftment and no ectopic tissue formation. Stem Cells (2012) 2.09
Adipose-derived mesenchymal stem cells ameliorate chronic experimental autoimmune encephalomyelitis. Stem Cells (2009) 1.95
A role for heme oxygenase-1 in the immunosuppressive effect of adult rat and human mesenchymal stem cells. Blood (2007) 1.91
Cell specific differences between human adipose-derived and mesenchymal-stromal cells despite similar differentiation potentials. Exp Cell Res (2008) 1.79
Differential expression of stem cell mobilization-associated molecules on multi-lineage cells from adipose tissue and bone marrow. Immunol Lett (2003) 1.73
Human MSC suppression correlates with cytokine induction of indoleamine 2,3-dioxygenase and bystander M2 macrophage differentiation. Mol Ther (2011) 1.70
Specific plasma membrane protein phenotype of culture-amplified and native human bone marrow mesenchymal stem cells. Blood (2007) 1.70
Cryopreserved mesenchymal stromal cells display impaired immunosuppressive properties as a result of heat-shock response and impaired interferon-γ licensing. Cytotherapy (2011) 1.65
CD40L induces inflammation and adipogenesis in adipose cells--a potential link between metabolic and cardiovascular disease. Thromb Haemost (2010) 1.63
Expression of the DNAM-1 ligands, Nectin-2 (CD112) and poliovirus receptor (CD155), on dendritic cells: relevance for natural killer-dendritic cell interaction. Blood (2005) 1.57
Optimization of in vitro expansion of human multipotent mesenchymal stromal cells for cell-therapy approaches: further insights in the search for a fetal calf serum substitute. J Cell Physiol (2007) 1.57
Anti-inflammatory protein TSG-6 reduces inflammatory damage to the cornea following chemical and mechanical injury. Proc Natl Acad Sci U S A (2010) 1.52
Bone marrow-derived mesenchymal stem cells induce both polyclonal expansion and differentiation of B cells isolated from healthy donors and systemic lupus erythematosus patients. Stem Cells (2008) 1.42
Mesenchymal stromal cell 'licensing': a multistep process. Leukemia (2011) 1.42
Human multipotent mesenchymal stromal cells use galectin-1 to inhibit immune effector cells. Blood (2010) 1.39
Stromal stem cells from adipose tissue and bone marrow of age-matched female donors display distinct immunophenotypic profiles. J Cell Physiol (2011) 1.36
GMP-compliant isolation and large-scale expansion of bone marrow-derived MSC. PLoS One (2012) 1.33
Interaction between human NK cells and bone marrow stromal cells induces NK cell triggering: role of NKp30 and NKG2D receptors. J Immunol (2005) 1.26
Adipose tissue-derived mesenchymal stem cells are more potent suppressors of dendritic cells differentiation compared to bone marrow-derived mesenchymal stem cells. Immunol Lett (2009) 1.22
DNAM-1 ligand expression on Ag-stimulated T lymphocytes is mediated by ROS-dependent activation of DNA-damage response: relevance for NK-T cell interaction. Blood (2011) 1.16
Post-translational regulation of human indoleamine 2,3-dioxygenase activity by nitric oxide. J Biol Chem (2007) 1.16
Inducible CD40 expression mediates NFkappaB activation and cytokine secretion in human colonic fibroblasts. Gut (2003) 1.10
Mesenchymal stem cells expanded in human platelet lysate display a decreased inhibitory capacity on T- and NK-cell proliferation and function. Eur J Immunol (2011) 1.07
Mesenchymal stromal cells cross-present soluble exogenous antigens as part of their antigen-presenting cell properties. Blood (2009) 1.06
Enhanced indoleamine 2,3-dioxygenase activity in patients with severe sepsis and septic shock. J Infect Dis (2010) 1.02
Critical role of the CD40 CD40-ligand pathway in regulating mucosal inflammation-driven angiogenesis in inflammatory bowel disease. Gut (2007) 1.01
Functional alteration of the lymphoma stromal cell niche by the cytokine context: role of indoleamine-2,3 dioxygenase. Cancer Res (2009) 0.99
Characterization and functionality of the CD200-CD200R system during mesenchymal stromal cell interactions with T-lymphocytes. Immunol Lett (2012) 0.95
Human adipose-derived stem cells impair natural killer cell function and exhibit low susceptibility to natural killer-mediated lysis. Stem Cells Dev (2011) 0.95
Platelet-derived growth factor BB promotes the migration of bone marrow-derived mesenchymal stem cells towards C6 glioma and up-regulates the expression of intracellular adhesion molecule-1. Neurosci Lett (2008) 0.92
Fibroblast growth factor 2 and platelet-derived growth factor, but not platelet lysate, induce proliferation-dependent, functional class II major histocompatibility complex antigen in human mesenchymal stem cells. Arthritis Rheum (2010) 0.92
Tryptophan catabolism is associated with acute GVHD after human allogeneic stem cell transplantation and indicates activation of indoleamine 2,3-dioxygenase. Blood (2011) 0.91
Fetal and adult multipotent mesenchymal stromal cells are killed by different pathways. Cytotherapy (2010) 0.87
A first approach for the production of human adipose tissue-derived stromal cells for therapeutic use. Methods Mol Biol (2011) 0.86
Fibroblast growth factor-2 enhances NK sensitivity of hepatocellular carcinoma cells. Int J Cancer (2011) 0.82
The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med (2006) 6.90
Clinical treatment of radiotherapy tissue damage by lipoaspirate transplant: a healing process mediated by adipose-derived adult stem cells. Plast Reconstr Surg (2007) 4.00
A differentiation checkpoint limits hematopoietic stem cell self-renewal in response to DNA damage. Cell (2012) 3.21
Immunomodulatory effect of human adipose tissue-derived adult stem cells: comparison with bone marrow mesenchymal stem cells. Br J Haematol (2005) 3.12
Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation (EBMT). Haematologica (2007) 3.03
BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood (2003) 2.82
Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood (2007) 2.76
Mechanically Isolated Stromal Vascular Fraction Provides a Valid and Useful Collagenase-Free Alternative Technique: A Comparative Study. Plast Reconstr Surg (2016) 2.66
Cdc42 activity regulates hematopoietic stem cell aging and rejuvenation. Cell Stem Cell (2012) 2.60
Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood (2007) 2.36
Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood (2002) 2.24
Clinical-grade production of human mesenchymal stromal cells: occurrence of aneuploidy without transformation. Blood (2009) 2.20
Bone marrow mesenchymal stem cells suppress lymphocyte proliferation in vitro but fail to prevent graft-versus-host disease in mice. J Immunol (2006) 2.16
Good manufacturing practices production of mesenchymal stem/stromal cells. Hum Gene Ther (2010) 2.15
Toll-like receptors 3 and 4 are expressed by human bone marrow-derived mesenchymal stem cells and can inhibit their T-cell modulatory activity by impairing Notch signaling. Stem Cells (2007) 2.12
Granulocyte-stimulating factor and severe aplastic anemia: a survey by the European Group for Blood and Marrow Transplantation (EBMT). Blood (2007) 2.09
Adipose-derived mesenchymal stem cells ameliorate chronic experimental autoimmune encephalomyelitis. Stem Cells (2009) 1.95
Human bone marrow and adipose tissue mesenchymal stem cells: a user's guide. Stem Cells Dev (2010) 1.78
Survival and proliferation factors of normal and malignant plasma cells. Int J Hematol (2003) 1.76
Specific plasma membrane protein phenotype of culture-amplified and native human bone marrow mesenchymal stem cells. Blood (2007) 1.70
A catalytic-independent role for the LUBAC in NF-κB activation upon antigen receptor engagement and in lymphoma cells. Blood (2014) 1.68
Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol (2013) 1.68
Telomerase gene mutations are associated with cirrhosis formation. Hepatology (2011) 1.67
A case of paroxysmal nocturnal hemoglobinuria caused by a germline mutation and a somatic mutation in PIGT. Blood (2013) 1.61
Human mesenchymal stem cells isolated from bone marrow and lymphoid organs support tumor B-cell growth: role of stromal cells in follicular lymphoma pathogenesis. Blood (2006) 1.58
Efficacy of Helicobacter pylori eradication in raising platelet count in adult patients with idiopathic thrombocytopenic purpura. Haematologica (2002) 1.54
Human mesenchymal stem cells respond to native but not oxidized damage associated molecular pattern molecules from necrotic (tumor) material. Eur J Immunol (2011) 1.54
Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays. Oncogene (2002) 1.53
Immunological characterization of multipotent mesenchymal stromal cells--The International Society for Cellular Therapy (ISCT) working proposal. Cytotherapy (2013) 1.52
Mesenchymal stem cells promote matrix metalloproteinase secretion by cardiac fibroblasts and reduce cardiac ventricular fibrosis after myocardial infarction. Stem Cells (2009) 1.51
Uptake mechanism of oppositely charged fluorescent nanoparticles in HeLa cells. Macromol Biosci (2008) 1.44
CD200 is a new prognostic factor in multiple myeloma. Blood (2006) 1.44
Characterization of a transitional preplasmablast population in the process of human B cell to plasma cell differentiation. J Immunol (2011) 1.42
Identification of IL-10 and TGF-beta transcripts involved in the inhibition of T-lymphocyte proliferation during cell contact with human mesenchymal stem cells. Gene Expr (2007) 1.41
Results of intracoronary stem cell therapy after acute myocardial infarction. Am J Cardiol (2010) 1.40
Bioactivity and prognostic significance of growth differentiation factor GDF15 secreted by bone marrow mesenchymal stem cells in multiple myeloma. Cancer Res (2012) 1.38
Specific lineage-priming of bone marrow mesenchymal stem cells provides the molecular framework for their plasticity. Stem Cells (2009) 1.37
Adult stromal cells derived from human adipose tissue provoke pancreatic cancer cell death both in vitro and in vivo. PLoS One (2009) 1.37
Deficiency of innate and acquired immunity caused by an IKBKB mutation. N Engl J Med (2013) 1.37
Bone marrow stromal cells and the upregulation of interleukin-8 production in human T-cell acute lymphoblastic leukemia through the CXCL12/CXCR4 axis and the NF-kappaB and JNK/AP-1 pathways. Haematologica (2008) 1.35
GMP-compliant isolation and large-scale expansion of bone marrow-derived MSC. PLoS One (2012) 1.33
Short-term injection of antiapoptotic cytokine combinations soon after lethal gamma -irradiation promotes survival. Blood (2002) 1.31
High-resolution HLA matching in hematopoietic stem cell transplantation: a retrospective collaborative analysis. Blood (2013) 1.30
Uptake of functionalized, fluorescent-labeled polymeric particles in different cell lines and stem cells. Biomaterials (2006) 1.30
Bone marrow versus peripheral blood as the stem cell source for sibling transplants in acquired aplastic anemia: survival advantage for bone marrow in all age groups. Haematologica (2012) 1.29
Sepsis induced changes of adipokines and cytokines - septic patients compared to morbidly obese patients. BMC Surg (2010) 1.28
Interleukin 21-induced granzyme B-expressing B cells infiltrate tumors and regulate T cells. Cancer Res (2013) 1.27
Risk of tumorigenicity in mesenchymal stromal cell-based therapies--bridging scientific observations and regulatory viewpoints. Cytotherapy (2013) 1.27
Impact of age on outcomes after bone marrow transplantation for acquired aplastic anemia using HLA-matched sibling donors. Haematologica (2010) 1.27
The human nose harbors a niche of olfactory ectomesenchymal stem cells displaying neurogenic and osteogenic properties. Stem Cells Dev (2010) 1.25
CXCR4 expression functionally discriminates centroblasts versus centrocytes within human germinal center B cells. J Immunol (2009) 1.24
Neuronal differentiation potential of human adipose-derived mesenchymal stem cells. Stem Cells Dev (2008) 1.24
Intracoronary autologous mononucleated bone marrow cell infusion for acute myocardial infarction: results of the randomized multicenter BONAMI trial. Eur Heart J (2010) 1.23
Toll-like receptor-3-activated human mesenchymal stromal cells significantly prolong the survival and function of neutrophils. Stem Cells (2011) 1.22
Influence of donor/recipient sex matching on outcome of allogeneic hematopoietic stem cell transplantation for aplastic anemia. Transplantation (2006) 1.21
Prospective study of rabbit antithymocyte globulin and cyclosporine for aplastic anemia from the EBMT Severe Aplastic Anaemia Working Party. Blood (2012) 1.20
Mesenchymal stem cells for therapeutic purposes. Transplantation (2009) 1.20
Ex vivo pretreatment with melatonin improves survival, proangiogenic/mitogenic activity, and efficiency of mesenchymal stem cells injected into ischemic kidney. Stem Cells (2008) 1.19
Stem molecular signature of adipose-derived stromal cells. Exp Cell Res (2007) 1.17
Limited acquisition of chromosomal aberrations in human adult mesenchymal stromal cells. Cell Stem Cell (2012) 1.16
Bone marrow mesenchymal stem cells: biological properties and their role in hematopoiesis and hematopoietic stem cell transplantation. Stem Cell Rev (2011) 1.16
Macrophages may promote cancer growth via a GM-CSF/HB-EGF paracrine loop that is enhanced by CXCL12. Mol Cancer (2010) 1.16
Mesenchymal stem cells and autoimmune diseases. Best Pract Res Clin Haematol (2011) 1.16
c-Kit-positive cardiac stem cells nested in hypoxic niches are activated by stem cell factor reversing the aging myopathy. Circ Res (2013) 1.15
CD40 ligand protects from TRAIL-induced apoptosis in follicular lymphomas through NF-kappaB activation and up-regulation of c-FLIP and Bcl-xL. J Immunol (2008) 1.15
Mesenchymal stromal cells: misconceptions and evolving concepts. Cytotherapy (2013) 1.14
Second allograft for hematologic relapse of acute leukemia after first allogeneic stem-cell transplantation from related and unrelated donors: the role of donor change. J Clin Oncol (2013) 1.13
Microarray-based understanding of normal and malignant plasma cells. Immunol Rev (2006) 1.12
Peptide nanofibrils boost retroviral gene transfer and provide a rapid means for concentrating viruses. Nat Nanotechnol (2013) 1.12
Eosinophils oxidize damage-associated molecular pattern molecules derived from stressed cells. J Immunol (2009) 1.12
Drug induced immune haemolytic anaemia in the Berlin Case-Control Surveillance Study. Br J Haematol (2011) 1.11
Concise review: growth differentiation factor 15 in pathology: a clinical role? Stem Cells Transl Med (2013) 1.11
Carboxylated superparamagnetic iron oxide particles label cells intracellularly without transfection agents. Mol Imaging Biol (2008) 1.10
Production of mesenchymal stromal/stem cells according to good manufacturing practices: a review. Stem Cell Res Ther (2013) 1.10
Comparative study of immune regulatory properties of stem cells derived from different tissues. Stem Cells Dev (2013) 1.08
mRNA-mediated gene delivery into human progenitor cells promotes highly efficient protein expression. J Cell Mol Med (2007) 1.08
Notch-3 and Notch-4 signaling rescue from apoptosis human B-ALL cells in contact with human bone marrow-derived mesenchymal stromal cells. Blood (2011) 1.08